This page summarizes published research on pulsed electromagnetic fields (PEMF) and osteoarthritis. It reports what named studies found and does not state what any device will do for a person with osteoarthritis.
This page covers one part of a wider topic. For the overview, see PEMF and Arthritis: What the Research Shows.
PEMF Osteoarthritis: What researchers have studied
Osteoarthritis research on electromagnetic fields has focused mostly on knee symptoms measured with patient questionnaires, pain scales, stiffness scores, and daily-activity measures. The better-known studies compared an active device with a sham device and used blinding, although the field characteristics, device designs, exposure schedules, outcome measures, and follow-up periods differed substantially. A smaller early trial also included osteoarthritis of the cervical spine, which is not interchangeable with knee osteoarthritis. The reviews below combine studies of electromagnetic-field approaches, not necessarily one identical device format or waveform.
The original page also listed two historical conference reports without a traceable PMID or DOI. They are not used in the visible evidence assessment. Both are documented in the preservation audit for editorial review.
The studies
Cochrane review of electromagnetic-field trials
Li and colleagues updated a Cochrane systematic review of randomized trials lasting at least four weeks. It included nine studies and 636 participants with osteoarthritis. In the pooled analysis, participants assigned to electromagnetic fields rated pain relief 15.10 points higher on a 0-to-100 scale than placebo after four to 26 weeks. The review found no statistically significant difference for physical function or quality of life, and it had no data to analyze radiographic change. The authors also reported unclear selective-reporting risk in all nine trials and high risk from incomplete outcome data in three. Because the review grouped electromagnetic-field interventions and the individual studies varied, its pooled result does not establish what a particular PEMF device would do for a particular joint.
Li S, Yu B, Zhou D, He C, Zhuo Q, Hulme JM. “Electromagnetic fields for treating osteoarthritis.” Cochrane Database of Systematic Reviews. 2013;(12):CD003523. DOI: 10.1002/14651858.CD003523.pub2. PMID: 24338431.
2020 systematic review and meta-analysis
Yang and colleagues reviewed 16 randomized, placebo-controlled trials; 15 supplied complete data for meta-analysis. Their pooled results favored PEMF over placebo for pain, stiffness, and physical function, while the quality-of-life estimate crossed the null value. The review found no association between the PEMF parameters examined and symptom results. The authors described the evidence as limited to short-term effects and called for more research on quality of life. A pooled average can conceal important differences among devices, joints, participant groups, and outcome timing. This review therefore describes the pattern in its included trials rather than a result for any retail device.
Yang X, He H, Ye W, Perry TA, He C. “Effects of Pulsed Electromagnetic Field Therapy on Pain, Stiffness, Physical Function, and Quality of Life in Patients With Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.” Physical Therapy. 2020;100(7):1118–1131. DOI: 10.1093/ptj/pzaa054. PMID: 32251502.
2009 meta-analysis of knee trials
Vavken and colleagues pooled nine randomized, blinded comparisons involving 483 people with knee osteoarthritis. They found no statistically significant pooled difference for pain or stiffness. They did find statistically significant differences for activities of daily living and clinical scores. That split result is important because it does not support a uniform conclusion across every outcome. The analysis was based on the trials then available, and the authors noted continuing uncertainty about pain. It also applies to knee osteoarthritis, not automatically to osteoarthritis in the hip, hand, shoulder, or spine.
Vavken P, Arrich F, Schuhfried O, Dorotka R. “Effectiveness of pulsed electromagnetic field therapy in the management of osteoarthritis of the knee: a meta-analysis of randomized controlled trials.” Journal of Rehabilitation Medicine. 2009;41(6):406–411. DOI: 10.2340/16501977-0374. PMID: 19479151.
Trock, Bollet, and Markoll randomized trials
Trock, Bollet, and Markoll reported randomized, double-blind, placebo-controlled trials of osteoarthritis of the knee and cervical spine. The knee study enrolled 86 people and the cervical-spine study enrolled 81. Each compared 18 active or placebo half-hour exposures and assessed participants through one month after the exposures ended. In the knee trial, the active group had greater improvement than placebo for pain, pain on motion, and participant and physician global assessments at the end of the study exposures. The cervical-spine results reached statistical significance for selected measures at one or more time points. The publication combines two body sites, uses outcomes that differ from later trials, and has short follow-up. Its knee findings do not establish results for other joints or later device designs.
Trock DH, Bollet AJ, Markoll R. “The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials.” Journal of Rheumatology. 1994;21(10):1903–1911. PMID: 7837158.
Pipitone and Scott knee trial
Pipitone and Scott conducted a six-week randomized, double-blind, placebo-controlled trial in 75 people with symptomatic knee osteoarthritis from one tertiary referral center; 69 were analyzed after six did not return after screening. The study found no statistically significant between-group difference for any outcome at the end of the study. Within the active group, some scores improved from baseline, while the placebo group did not show comparable within-group changes. The lack of a significant active-versus-sham comparison is the key result for assessing the trial. Its single-center sample, attrition before analysis, and six-week duration limit how much can be inferred beyond that study population and device.
Pipitone N, Scott DL. “Magnetic pulse treatment for knee osteoarthritis: a randomised, double-blind, placebo-controlled study.” Current Medical Research and Opinion. 2001;17(3):190–196. DOI: 10.1185/0300799039117061. PMID: 11900312.
Thamsborg and colleagues’ knee trial
Thamsborg and colleagues randomized 83 people with knee osteoarthritis in a double-blind, placebo-controlled trial. Participants used active or placebo equipment for two hours a day, five days a week, for six weeks; assessments continued six weeks after that period. Within-group scores improved in the active group, but the primary between-group analysis did not show significant improvement over time in the full sample. Among participants younger than 65, the between-group analysis found a stiffness difference at two weeks, but not differences for pain or daily activities. The authors did not demonstrate a symptomatic difference for all participants. The subgroup result is narrower than the overall null comparison and needs cautious interpretation.
Thamsborg G, Florescu A, Oturai P, Fallentin E, Tritsaris K, Dissing S. “Treatment of knee osteoarthritis with pulsed electromagnetic fields: a randomized, double-blind, placebo-controlled study.” Osteoarthritis and Cartilage. 2005;13(7):575–581. DOI: 10.1016/j.joca.2005.02.012. PMID: 15979009.
Wuschech and colleagues’ placebo-controlled study
Wuschech and colleagues reported a prospective, placebo-controlled, double-blind study in 57 people with knee osteoarthritis. The paper describes the allocation as partly randomized and compared an active device with a placebo device over 18 days. The active group had statistically significant differences from control on WOMAC pain, stiffness, and daily-activity scales, while the placebo group did not have significant change from its first to final assessment on those scales. The brief study period, small sample, and partly randomized allocation are immediate limitations. The paper’s results concern the device and participant group studied; they do not establish whether those findings apply to another device, another exposure pattern, another joint, or longer follow-up.
Wuschech H, von Hehn U, Mikus E, Funk RH. “Effects of PEMF on patients with osteoarthritis: Results of a prospective, placebo-controlled, double-blind study.” Bioelectromagnetics. 2015;36(8):576–585. DOI: 10.1002/bem.21942. PMID: 26562074.
How strong is this evidence?
The evidence is mixed and limited, rather than settled. Several randomized, sham-controlled studies and two systematic reviews provide a stronger starting point than uncontrolled reports. At the same time, the trials used different field specifications, equipment, schedules, outcomes, and analytic approaches. That heterogeneity makes it difficult to treat “PEMF” as one uniform exposure or to transfer a result from the tested equipment to a different device.
The outcome pattern is not consistent. The 2009 meta-analysis found no statistically significant pooled difference for pain or stiffness, while finding differences for activities of daily living and clinical scores. The 2013 Cochrane review found a pooled pain-relief difference but no statistically significant function or quality-of-life difference, and it found no radiographic-change data. The 2020 review reported pooled differences favoring PEMF for several symptom outcomes but said that the evidence was short term and that quality-of-life effects required further study. Individual trials also conflict: Pipitone and Scott found no significant active-versus-sham difference, and Thamsborg and colleagues did not show a full-sample between-group difference over time.
Most direct evidence is for the knee, with small to moderate samples and follow-up measured in weeks, not years. Some reports have incomplete reporting, attrition, or partly randomized allocation. Replication with clearly described devices, pre-specified outcomes, longer follow-up, and independent teams would make the literature easier to interpret. None of these studies establishes an effect on joint structure, disease progression, or outcomes for every person with osteoarthritis.
What this means if you are considering a PEMF device
The published human studies discussed here mainly placed the field at a named, localized joint, especially the knee. For someone comparing formats, a portable applicator is the format most directly comparable in placement to research directed at a localized joint. That is a format comparison, not evidence that a portable applicator produces the study findings or that any device is appropriate for osteoarthritis.
Knee-specific findings should remain knee-specific. The Trock paper also studied the cervical spine, but that does not make it evidence for every spinal, hip, hand, foot, or shoulder presentation. Full-body mats and localized applicators differ in placement and design, and the older studies used equipment that may not match current retail products. When comparing device information, it is reasonable to separate what a manufacturer documents about its own device from what named studies reported about their research equipment. The portable PEMF machine guide and PEMF mat versus PEMF machine comparison describe those format distinctions.
Questions to ask before buying
- Does the manufacturer provide the waveform, frequency range, field strength, and applicator dimensions in writing?
- Is the format a portable applicator or a mat, and how does its placement compare with the localized joint placement used in the studies?
- Which accessories, power options, carrying components, and replacement parts are included in the listed price?
- What do the written warranty, return window, shipping costs, and restocking terms say?
- Can the seller provide the user manual and product specifications before purchase?
This page summarizes published research for reference. It is not medical advice, and nothing here is a claim that any PEMF device treats, cures, or prevents any condition. PEMF is not appropriate for everyone — review PEMF contraindications and talk with your own physician before beginning any new therapy, particularly if you have an implanted electronic device, are pregnant, or are being treated for a serious medical condition.